Article Text

PDF
DI-096 Refractory lance–adams syndrome: pharmacotherapy management and iatrogenic complications
  1. E Lázaro López1,
  2. MM Jalón Urbina2,
  3. AI Plano Sánchez1,
  4. A Rodríguez Ferreras1,
  5. C Carriles Fernández1,
  6. I Zapico García1,
  7. L Velasco Roces1,
  8. L Gómez de Segura Iriarte3
  1. 1Hospital Universitario Central de Asturias, Hospital Pharmacy, Oviedo, Spain
  2. 2Hospital Universitario Central de Asturias, Mental Health Department, Oviedo, Spain
  3. 3Hospital Universitario San Agustín, Hospital Pharmacy, Avilés, Spain

Abstract

Background Lance–Adams syndrome (LAS) is a chronic post-hypoxic myoclonus that may appear after a period of cerebral hypoxia. Many different antiepileptic drugs (AED) have been used for the symptomatic control of LAS. In the absence of response to classic AED, it is necessary to consider new off-label therapeutic options which may cause unpredictable adverse events.

Purpose To present the pharmacotherapy approach to a case of refractory LAS, describing treatment related adverse events and its management.

Material and methods We describe the case of a 35-year-old active male smoker with antecedents of three consecutive cardiac arrests that led to the development of LAS. The clinical information was collected from the electronic medical records (Cerner Millennium). A literature review was conducted looking for evidence of the use of perampanel, 5-hydroxytryptophan (5-HT) and sodium oxybate in LAS. Adverse events information was obtained from the drugs’ EPAR.

Results At admission, the patient was treated with levetiracetam, sodium valproate and then sedated with propofol and sodium thiopental. As myoclonus was not controlled, piracetam, zonisamide (to reduce the use of sedative drugs) and clonidine were added to the previous treatment, without obtaining improvement. Sodium oxybate was added, but it was discontinued early due to the risk of respiratory arrest. 5-HT also was added with no significant outcome and severe diarrhoea as an adverse event. Finally, perampanel (24 mg/day—maximum daily dose doubled) was added to the treatment, achieving myoclonus improvement. Simultaneously, the patient had behavioural disorders that were linked with perampanel treatment, needing addition of risperidone. Finally, LAS control was achieved and the patient was discharged with levetiracetam, gabapentin, perampanel and risperidone treatment.

Conclusion The refractory nature of LAS forced the medical team to use off-label drugs and supratherapeutic doses, with increased frequency of adverse events. The drug related events were identified and properly managed, allowing treatment continuation and ensuring patient improvement.

References and/or acknowledgements Suchitra Malhotra and Kumar Mohinder. Lance–Adams syndrome: Difficulties surrounding diagnosis, prognostication, and treatment after cardiac arrest. Anesth Essays Res2012;6:218–22.

No conflict of interest

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.